For further details see:
Supernus up 10% following 2021 earnings guidance boost, Q3 beatFor further details see:
Supernus up 10% following 2021 earnings guidance boost, Q3 beatMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Supernus Pharmaceuticals Inc. Company Name:
SUPN Stock Symbol:
Market:
Supernus Pharmaceuticals Inc. Website:
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing...
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and confe...
Net sales of Qelbree ® increased 75% to $45.1 million compared to first quarter 2023. Total revenues were $143.6 million. Total revenues excluding Trokendi XR ® and Oxtellar XR ® net product sales (non-GAAP) (1) increased 12% to $100.7 million compared to first ...